MagReSyn® Streptavidin

High capacity for capture of biotinylated molecules

MagReSyn® Streptavidin microparticles contain covalently coupled streptavidin. The porous nature of the polymer technology allows for exceptional streptavidin capacity, translating into increased capacity for the immobilization/capture of biotinylated biomolecules. The high streptavidin load allows the use of as little as 10 µl beads, improving experimental miniaturization for high-throughput automated analysis. Molecular applications of MagReSyn® Streptavidin microparticles include, protein immobilization and purification; nucleic acid capture assays and preparation of single-stranded DNA templates for e.g. SELEX and pyrosequencing. The immobilization of biotinylated antibodies may subsequently be used in e.g. immunoassay.

Support: Proprietary polymer microparticles containing iron oxide (magnetite) with immobilised Streptavidin
Binding capacity (DNA): > 30 000 pmoles.ml-1 (Biotinylated oligo, 25-mer)
Binding capacity (Protein): > 3 mg.ml-1 (Biotinylated IgG)
Bead size: ~5-10 µm average
Formulation: 10 mg.ml-1 suspension in sodium phosphate buffer

ORDER NOW

MagReSyn® Streptavidin MAX

Ultra-capacity for capture of biotinylated molecules

MagReSyn® Streptavidin MAX microparticles have been specially engineered for custom applications where maximum binding of biotinylated molecules is required. This includes microplate applications where miniaturization and high-throughput automated analysis are required.

Binding capacity (DNA): > 120 000 pmoles.ml-1 (Biotinylated oligo, 25-mer)
Binding capacity (Protein): > 5 mg.ml-1 (Biotinylated IgG)
Bead size: ~5-10 µm
Formulation: 10 mg.ml-1 suspension in sodium phosphate buffer

* Please note that MagReSyn® Streptavidin MAX is a custom product and requires 2 weeks lead time from date of order *

ORDER NOW

Product Resources

MagReSyn® Streptavidin Performance Superiority

Superior capacity

MagReSyn® Streptavidin

  • >3 000 pmoles.mg-1 (Biotinylated oligo, 25-mer)
  • >300 µg.mg-1 (Biotinylated IgG)

MagReSyn® Streptavidin MAX

  • MAX: >12 000 pmoles.mg-1 
  • MAX: >500 µg.mg-1 

High volumetric streptavidin loading allows unparalleled miniaturization and automation of experimentation

Exceptional stability

Highly stable multipoint covalent attachment of Streptavidin minimizes leaching

Excellent Value

  • Bind in excess of 5000 µg biotinylated IgG per product compared to less than 3000 µg biotinylated IgG for alternate products
  • Bind in excess of 60 000 pmoles biotinylated oligo per product compared to 25 000 pmoles biotinylated oligo per product for alternate products

MagReSyn® Streptavidin microparticles provide superior binding capacity for biotinylated oligos and protein compared to alternate suppliers. MagReSyn® Streptavidin MAX provides an high capacity for biotinylated oligo and protein binding for specialized applications. Green bars represent MagReSyn®, orange bars represent alternate suppliers products.

TERMS AND CONDITIONS
Products supplied by ReSyn Biosciences (Pty) Ltd are for research purposes only. ReSyn products are not to be used for diagnostic, therapeutic or commercial means any use resulting in monetary gain, including, but not limited to, incorporation in a kit, repackaging and re-formulation. Please enquire about sub-licenses for commercial use.

Citations and References

BioID based proteomic analysis of the Bid interactome identifies novel proteins involved in cell cycle dependent apoptotic priming

–   Robert Pedley et al.

BIORXIV (2020)

MagReSyn® Streptavidin

Definition of the fibroblast adhesome using multiplexed proximity biotinylation

–   Megan R. Chastney et al.

BIORXIV (2020)

MagReSyn® Streptavidin

BioID based proteomic screen identifies VDAC2 as a coordinator of Bid dependent apoptotic priming during mitosis

–   Robert Pedley et al.

BIORXIV (2019)

MagReSyn® Streptavidin

Immune genes are primed for robust transcription by proximal long noncoding RNAs located in nuclear compartments

–   Stephanie Fanucchi et al.

NATURE GENETICS (2018)

MagReSyn® Protein A, MagReSyn® Protein G, MagReSyn® Streptavidin

ADAP1 limits neonatal cardiomyocyte hypertrophy by reducing integrin cell surface expression

–   Hugo Giguère et al.

SCIENTIFIC REPORTS 8 (2018)

MagReSyn® Streptavidin

Identification of lipopolysaccharide-interacting plasma membrane-type proteins in Arabidopsis thaliana

–   Cornelius Vilakazi et al.

PLANT PHYSIOLOGY AND BIOCHEMISTRY (2017)

MagReSyn® Streptavidin

Effective immunotherapy of rat glioblastoma with prolonged intratumoral delivery of exogenous heat shock protein Hsp70

–   Maxim A. Shevtsiov et al.

INTERNATIONAL JOURNAL OF CANCER 135 (2014)

MagReSyn® Streptavidin